You are here: Industry Insights > TREMFYA

News List

Crohn’s patients achieve 65 percent clinical remission with Tremfya? EuropeanPharmaceuticalReview
November 18, 2021
Janssen has announced topline results from the Phase II GALAXI 1 clinical trial which showed rates of clinical remission – Crohn’s Disease Activity Index [CDAI]<150 – previously reported at week 12 increased at week...
Tremfya? shows promise in Phase III psoriatic arthritis study EuropeanPharmaceuticalReview
November 03, 2021
Janssen has announced six new analyses of Phase III data from the DISCOVER-1 and DISCOVER-2 clinical trials?, which demonstrate Tremfya? (guselkumab) inhibited radiographic progression versus placebo...
J&J's 2Q Pharma Sales Up 17% contractpharma
July 30, 2021
STELARA and DARZALEX sales drive growth with sales up 34% to $2.3 billion and up 59% to $1.4 billion in the quarter, respectively.
Johnson & Johnson reports 27.1% increase in Q2 2021 sales pharmaceutical-technology
July 23, 2021
Johnson & Johnson (J&J) has reported sales of $23.31bn in the second quarter (Q2) of 2021, an increase of 27.1% compared to $18.33bn in the same quarter last year.
Tremfya? improves psoriatic arthritis joint function and skin clearance europeanpharmaceuticalreview
June 08, 2021
Over 50 percent of psoriatic arthritis patients treated with Tremfya? (guselkumab) achieved ≥20 percent improvement in joint symptoms and complete skin clearance at one year.
J&J’s Tremfya shows significant improvements for post-TNFi psoriatic arthritis patients pharmatimes
June 04, 2021
Johnson & Johnson’s (J&J) interleukin-23 (IL-23) Tremfya has demonstrated positive results in post-tumour necrosis factor (TNF) inhibitor-treated psoriatic arthritis (PsA) patients.
NICE green lights Tremfya to treat active psoriatic arthritis pharmatimes
June 01, 2021
Janssen’s IL-23 inhibitor Tremfya has been accepted for NHS use by the UK’s National Institute for Health and Care Excellence (NICE) for the treatment of active psoriatic arthritis (PsA).
Johnson & Johnson 1Q Results contractpharma
April 21, 2021
Pharmaceutical sales up 10% in the quarter driven by DARZALEX, STELARA, INVEGA SUSTENNA, and IMBRUVICA.
Data shows long-term efficacy of Tremfya? in active psoriatic arthritis europeanpharmaceuticalreview
March 18, 2021
The joint and skin response rates of adults with active psoriatic arthritis observed with Tremfya? (guselkumab) were maintained over two years.
Janssen's Tremfya approved for active psoriatic arthritis pharmatimes
November 27, 2020
The European Commission has approved Janssen’s Tremfya (guselkumab) as a first-in-class treatment for active psoriatic arthritis (PsA).